Itraconazole (ITZ)

DRUG5 trials

Sponsors

AbbVie, Alexandria University, Multan Medical And Dental College

Conditions

Biliary Tract CancersDermatophytosisEsophageal Squamous Cell CarcinomaHead and Neck Squamous-Cell CarcinomaHealthy VolunteerHepatocellular CarcinomaHormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast CancerPancreatic Ductal Adenocarcinoma

Phase 1

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Active, not recruitingNCT06084481

AbbVieBiliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous-Cell Carcinoma +5

Start: 2023-11-09End: 2026-07-01Updated: 2026-01-20

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

TerminatedNCT06579300

AbbVieHealthy Volunteer

Start: 2024-09-04End: 2025-09-03Updated: 2025-10-30

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

CompletedNCT06722430

AbbVieHealthy Volunteer

Start: 2024-11-13End: 2025-01-13Updated: 2025-01-28

Unknown Phase

Comparison Between Continuous and Pulse Itraconazole in Tinea Capitis in Children

RecruitingNCT07184203

Alexandria UniversityTinea Capitis

Start: 2025-03-09End: 2025-12-31Target: 120Updated: 2025-09-19

Comparison of Combination of Itraconazole and Isotretinoin Versus Itraconazole Alone in the Treatment of Resistant Trichophyton Infection

CompletedNCT07420894

Multan Medical And Dental CollegeDermatophytosis, Resistant Dermatophyte Infection, Trichophyton Infection

Start: 2025-01-29End: 2025-07-28Updated: 2026-02-19

Related Papers

Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications.

Journal of Clinical Oncology2024-06-01